DANIELLE KENNEDY: Open Payments
NPI 1063118404 · HILLSBORO, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,505 in 94 payments from 13 companies in 2025. Trend: 2023 $842 · 2024 $1,712 · 2025 $1,505
Food & beverage: $1,505
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 13 | $275 |
| E.R. Squibb & Sons, L.L.C. | 25 | $242 |
| Neurocrine BioSciences, Inc. | 13 | $200 |
| Otsuka America Pharmaceutical, Inc. | 9 | $172 |
| Alkermes, Inc. | 7 | $122 |
| Supernus Pharmaceuticals, Inc. | 12 | $114 |
| ABBVIE INC. | 5 | $107 |
| Teva Pharmaceuticals USA, Inc. | 1 | $101 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $63 |
| Axsome Therapeutics, Inc. | 3 | $54 |
Products named: COBENFY, INGREZZA, INVEGA SUSTENNA, SPRAVATO, ARISTADA, Qelbree, VRAYLAR, UZEDY.
Industry payments across MO — which companies pay providers there.
